Holen Sie sich die Stockscreener-App
0.4349
6.05%
0.0248
Handel nachbörslich:
.44
0.0051
+1.17%
Applied Therapeutics Inc Aktie (APLT) Neueste Nachrichten
APLT stock touches 52-week low at $0.42 amid sharp annual decline - Investing.com
Charles Schwab Investment Management Inc. Has $600,000 Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics Delays Yearly Report Filing - TipRanks
Applied Therapeutics files Form 12b-25 with SEC - TipRanks
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission - GlobeNewswire
Applied Therapeutics Requests SEC Extension: What This Means for 2024 Financial Results - Stock Titan
146,900 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Swiss National Bank - Defense World
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Lost Money on Applied Therapeutics, Inc.(APLT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Applied Therapeutics appoints new Chief Regulatory Officer By Investing.com - Investing.com South Africa
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer - citybiz
APLT DEADLINE ALERT: Applied Therapeutics Investors have until February 18 before Expiration of the Class Action DeadlineContact BFA Law if You Lost Money - Louisiana First News
Applied Therapeutics Names Todd Baumgartner As Chief Regulatory Officer - Nasdaq
Applied Therapeutics appoints new Chief Regulatory Officer - Investing.com
Applied Therapeutics Strengthens Drug Approval Push With 12-Time FDA Success Veteran - Stock Titan
Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $6.10 - MarketBeat
Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
APPLIED THERAPEUTICS Earnings Preview: Recent $APLT Insider Trading, Hedge Fund Activity, and More - Nasdaq
A look into Applied Therapeutics Inc (APLT)’s deeper side - SETE News
Applied Therapeutics Inc (APLT) Announces Year-End 2023 Financia - GuruFocus.com
40,300 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Private Advisor Group LLC - Defense World
Shareholders of Applied Therapeutics, Inc. Should Contact The Gr - GuruFocus.com
Applied Therapeutics, Inc. Class Action: Levi & Korsinsky Remind - GuruFocus.com
Applied therapeutics COO Constantine Chinoporos sells $196 in stock - Investing.com India
Applied Therapeutics (APLT) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Applied therapeutics’ interim CEO sells shares worth $6,380 - Investing.com India
Applied Therapeutics chief medical officer sells shares worth $4,561 - Investing.com India
Applied Therapeutics chief medical officer sells shares worth $4,561 By Investing.com - Investing.com UK
Monitoring Applied Therapeutics Inc (APLT) after recent insider movements - Knox Daily
APLT Deadline: APLT Purchasers Have Opportunity to Lead Applied Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics - GuruFocus.com
Levi & Korsinsky Notifies Shareholders of Applied Therapeutics, Inc. (APLT) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Class Action Filed Against Applied Therapeutics, Inc. (APLT)February 18, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
APLT stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com India
APLT stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com - Investing.com South Africa
Applied Therapeutics (APLT) to Release Earnings on Wednesday - Defense World
Shareholders that lost money on Applied Therapeutics, Inc.(APLT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Applied Therapeutics (APLT) Projected to Post Earnings on Wednesday - MarketBeat
Applied Therapeutics, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsAPLT - ACCESS Newswire
Market Fluctuations Drive Mega-Cap, Large-Cap, Mid-Cap, and Small-Cap Stocks in Wild Movements Today - HPBL
ATTENTION Applied Therapeutics, Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
APLT stock touches 52-week low at $0.54 amid sharp annual decline By Investing.com - Investing.com South Africa
APLT stock touches 52-week low at $0.54 amid sharp annual decline - Investing.com
Applied Therapeutics Inc (APLT) At $0.58 Is Well Worth Your Time - Stocks Register
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
2025-02-18 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. LawsuitAPLT | NDAQ:APLT | Press Release - Stockhouse Publishing
Shareholders of Applied Therapeutics, Inc. Should Contact The Gross Law Firm Before February 18, 2025 to Discuss Your RightsAPLT - PR Newswire
Applied Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics - Business Wire
DEADLINE ALERT for APLT and KSPI: The Law Offices of Frank - GlobeNewswire
2025-02-18 | Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT | NDAQ:APLT | Press Release - Stockhouse Publishing
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):